Sandoz announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva®* (denosumab 120 mg) and Prolia®* (denosumab 60 mg). Wyost® is approved for the treatment of cancer-related bone disease1 and Jubbonti® is approved to treat osteoporosis.
Wyost® and Jubbonti® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost® and Jubbonti® in the US and the recent launches of Tyruko® (natalizumab) in the US and Afqlir® (aflibercept) in Europe.
Christophe Delenta, President Europe, Sandoz, said: “We know that primary and secondary bone loss, and cancer-related bone events, place a significant burden on millions of patients and their families, as well as on European healthcare systems. That’s why the launch of these denosumab biosimilars is such an important milestone, expanding access to these potentially life-changing medicines and reinforcing our commitment to delivering sustainable treatment options for patients.”
Close to one quarter (4.14 million)3 of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries4. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate5.
According to the latest figures, 32 million people in Europe over 50 years old are estimated to live with osteoporosis, with the number of fractures per year set to increase by almost 25% by 20346. Only a minority of patients at high risk currently receive treatment, even after their first fracture7.
Wyost® and Jubbonti® will be launched across Europe, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion8 and reinforces its established position in oncology and immunology.
*Xgeva® and Prolia® are registered trademarks of Amgen Inc.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!